Navigation Links
Senetek PLC in Dispute With Marketer of Pyratine-6(TM)
Date:3/4/2008

Investor Update Conference Call Set for March 7

NAPA, Calif., March 4 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced it has entered into a contractual dispute resolution process with Triax Aesthetics LLC, the privately-held specialty pharmaceuticals marketer which Senetek licensed in August 2007 to sell a line of skincare products featuring Senetek's new Pyratine-6(TM) active ingredient to dermatologists and other physicians who prescribe or dispense products and to chain drug stores for sale at the pharmacist's counter.

Senetek also announced that it will conduct a teleconference for investors on Friday, March 7, 2008 at 9:00 a.m. Pacific time, 12:00 p.m. Eastern time, at which Senetek management will give an update on the business including the appointment of two veteran sales and marketing executives and a Vice President of Communications. The domestic dial-in number will be 877-593-8638 and the international dial-in number will be 706-634-9240, conference ID 37979186. Replay of the conference call will be available until March 14, 2008, domestic replay dial-in 800-642-1687, international replay dial-in 706-645-9291, replay conference ID 37979186.

About Senetek PLC

Senetek PLC (OTC Bulletin Board: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market. For more information, visit the company's website at http://www.senetekplc.com.

This news release contains statements that may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2006. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Senetek PLC
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
2. Patent Office Rules in Neuralstems Favor in Dispute with StemCells, Inc.
3. Pyratine-6(TM) Study Published in Journal of Drugs in Dermatology
4. Dr. Mark Nestor Presents on Pyratine-6(TM) at the South Beach Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... (NYSE MKT: ISR), a medical technology company and innovator ... treatment of prostate, brain, lung, head and neck and ... second quarter and six months of fiscal 2016, which ... --> Revenue was $1.19 million for ... 31, 2015, a 12% increase compared to $1.07 million ...
(Date:2/10/2016)... ... February 10, 2016 , ... Benchmark ... today the promotion of two long-standing principal investigators (PI) to the roles of ... Research and Development. , Dr. Laurence Chu, a Benchmark Research PI in the ...
(Date:2/10/2016)... ... 2016 , ... SonaCare Medical, LLC reports the introduction of ... monitoring. The inaugural launch of this new technology occurred over the course of ... to a HIFU technical expert at SonaCare Medical headquarters. , Sonalink allows ...
(Date:2/10/2016)... , ... February 10, 2016 , ... ... medicine, has announced a new agreement with Singapore-based Global Stem Cells Network (GSCN) ... the Philippines, Thailand and Singapore in the latest adipose and bone marrow therapies. ...
Breaking Biology Technology:
(Date:2/2/2016)... 2, 2016 Checkpoint Inhibitors for Cancer ... Are you interested in the future of ... checkpoint inhibitors. Visiongain,s report gives those predictions to ... national level. Avoid falling behind in data ... and revenues those emerging cancer therapies can achieve. ...
(Date:2/1/2016)... 1, 2016  Today, the first day of American ... to develop a first of its kind workplace health ... Watson. In the first application of Watson ... IBM ), and Welltok will create a new offering ... cognitive analytics, delivered on Welltok,s health optimization platform. The ...
(Date:1/25/2016)... 2016  Glencoe Software, the world-leading supplier of image ... will provide the data management solution OMERO Plus for ... Photo - ... Phenotypic analysis measures the characteristics and behavior ... between states such as health and disease, the presence ...
Breaking Biology News(10 mins):